Last updated: February 23, 2026
What is NDC 42858-0402?
NDC 42858-0402 refers to a specific pharmaceutical product listed in the National Drug Code (NDC) database. Based on available data, this code is associated with Atezolizumab (brand name Tecentriq), a monoclonal antibody used in oncology, primarily for non-small cell lung carcinoma, urothelial carcinoma, and other cancers.
Market Landscape
Market Size
Atezolizumab belongs to the immune checkpoint inhibitor class. The global oncology immunotherapy market was valued at approximately USD 50 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 12% through 2028[1].
Key indications for NDC 42858-0402:
| Indication |
Global Market Size (2022, USD) |
Growth Rate (2022-2028) |
| Non-small cell lung cancer |
12 billion |
13% |
| Urothelial carcinoma |
8 billion |
11% |
| Other solid tumors |
7 billion |
10% |
Competitive Landscape
Major competitors in the immuno-oncology space include:
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Avelumab (Bavencio)
- Durvalumab (Imfinzi)
Market share among these drugs remains dynamic. As of 2022, Keytruda leads with approximately 45% of immunotherapy sales, followed by Opdivo at 30%[2].
Regulatory Approvals
Atezolizumab received FDA approval in 2016 across several indications, including metastatic non-small cell lung cancer. Additional approvals in Spain, Japan, and EU countries broaden its market access.
Price Trends and Projections
Current Pricing Data
The acquisition and list prices for NDC 42858-0402 (Atezolizumab) vary. In the U.S., the average wholesale price (AWP) for a 1200 mg dose (typical for adult treatment) is around USD 10,000 per vial, with some variation based on negotiated discounts, insurance coverage, and pharmacy benefits[3].
| Price Metrics |
2022 Data |
Notes |
| Average Wholesale Price |
USD 10,000 per 1200 mg vial |
List price, before discounts and rebates |
| Medicare mean reimbursed cost |
USD 8,500 per dose |
Average reimbursement rate in Medicare Part B |
| Private insurer reimbursement |
USD 8,200–8,800 per dose |
Based on negotiated contracts |
Price Trends
Atezolizumab's list price has remained relatively stable since its launch, with minor adjustments for inflation and supply factors. The key drivers for future price changes include:
- Patent expirations in certain jurisdictions (expected around 2030)
- Biosimilar entry due to biosimilar pathway approvals
- Competitive pressure from other immunotherapies
- Cost control policies implemented by healthcare providers
Price Projections (2023–2030)
| Year |
Expected Average Price (USD) per Dose |
Rationale |
| 2023 |
USD 9,800 |
Stable, slight discounting expected |
| 2025 |
USD 9,000 |
Potential price compression from biosimilars |
| 2028 |
USD 8,200 |
Increased biosimilar market penetration |
| 2030 |
USD 7,500 |
Patent loss and regulatory policies influence prices |
Biosimilar Impact
The biosimilar pathway is expected to emerge by 2028-2030, with biosimilar versions potentially reducing prices by 20-40% upon market entry[4].
Key Factors Influencing Market and Price Dynamics
- Patent life: Patent expiration around 2030 influences price competition.
- Manufacturing costs: Advances in bioprocessing could lower production costs, impacting pricing.
- Regulatory policies: Governments and payers emphasizing cost-effectiveness may impose price caps or favor biosimilars.
- Market demand: Rising incidence of target cancers supports steady volume growth but is moderated by competition.
Summary of Investment and R&D Implications
- Competitive positioning: Atezolizumab maintains a strong market share but faces intense competition.
- Pricing outlook: Marginal downward pressure is probable given biosimilar developments and policy measures.
- Market potential: Expected to grow at a CAGR of approximately 12% driven by expanding indications and global access initiatives.
Key Takeaways
- NDC 42858-0402 (Atezolizumab) is a mid-to-high cost biologic with a substantial market.
- Current prices are around USD 10,000 per dose; prices are projected to decline slowly, influenced by biosimilar entries.
- Market growth is driven by oncology indications with a forecast CAGR of 12% through 2028.
- Competition from other immune checkpoint inhibitors remains fierce, influencing pricing trajectories.
- Patent expiry and regulatory shifts will be critical determinants in future pricing and market share.
FAQs
Q1: How does the patent status impact future pricing for NDC 42858-0402?
A1: Patent expiration around 2030 will enable biosimilar entry, increasing competition and typically reducing prices by 20-40%.
Q2: Will biosimilars significantly affect the market share of Atezolizumab?
A2: Yes, biosimilars are expected to capture substantial market share post-2030, pressuring prices downward.
Q3: How do current prices compare globally?
A3: Prices are highest in the U.S., averaging USD 10,000 per dose. Prices in Europe and Asia generally range from USD 6,000 to USD 9,000, influenced by local reimbursement policies.
Q4: What clinical factors influence the demand for NDC 42858-0402?
A4: The approval for multiple cancer indications and combination therapies drive demand. Advancements in biomarker testing also expand eligible patient populations.
Q5: How are payer policies expected to influence pricing strategies?
A5: Payers push for cost containment through negotiated discounts, prior authorization, and encouraging biosimilar use, impacting list prices and margins.
References
- MarketWatch. (2022). Oncology Immunotherapy Market Size, Share & Trends. Retrieved from https://www.marketwatch.com/
- IQVIA. (2022). Global Oncology Market Report.
- Xcenda. (2022). Biologic and Biosimilar Pricing Data.
- Congressional Budget Office. (2020). Biosimilar Competition and Pricing.
